期刊文献+

金水宝联合依那普利治疗糖尿病肾病随机平行对照研究 被引量:2

Randomized Parallel Controlled Study Jinshui Bao and Enalapril in the Treatment of Diabetic Nephropathy
下载PDF
导出
摘要 [目的]观察金水宝联合依那普利治疗糖尿病肾病疗效。[方法]使用随机平行对照方法,将44例门诊患者按随机数字表法随机分为两组。对照组22例依那普利,10mg/次,1次/d,口服。治疗组22例金水宝,3粒/次,3次/d、口服依那普利治疗同对照组。治疗30d为1疗程。观测临床症状、24h尿微量白蛋白、血糖、血压、血常规、血生化、肝功能、不良反应。连续治疗3个疗程,判定疗效。[结果]治疗组显效11例,有效10例,无效1例,总有效率95.45%。对照组显效5例,有效6例,无效11例,总有效率50.00%。治疗组疗效优于对照组(P<0.05)。治疗前、后24h尿微量白蛋白治疗组优于对照组(P<0.05)。[结论]金水宝联合依那普利治疗糖尿病肾病效果显著,值得推广。 [ Objective ] To observe the curative effect of Jinshui treasure and enalapril in the treatment of diabetic nephropathy. [ Method ] Using random parallel control method, 44 cases of outpatients were randomly divided into two groups. The control group of 22 cases with enalapril, 10mg/, 1/d, oral. The treatment group of 22 eases of Jinshui Bao, 3 capsules each time, 3 times/d, enalapril treatment with the control group. For the 1 course of treatment of 30D. Observation of clinical symptoms, 24h urinary albumin, blood glucose, blood pressure, blood routine test, blood biochemistry, liver function, adverse reaction. Continuous treatment of 3 courses of treatment, curative effect. 11 cases of the treatment group produce [ Results ] Effective 10 cases, invalid 1 cases, the total efficiency of 95.45%. The control group was 5 cases, effective 6 cases, invalid 11 cases, the total efficiency of 50%. The efficacy of the treatment group was better than that of the control group ( P 〈 0.05 ) . Before and after treatment, urine micro albumin in 24h treatment group than in control group ( P 〈 0.05 ) . [ Conclusion ] Jinshui Bao combined with enalapril in treatment of diabetic nephropathy with significant effect, worthy of promotion.
作者 王天平
机构地区 四川绵阳四
出处 《实用中医内科杂志》 2014年第11期77-79,共3页 Journal of Practical Traditional Chinese Internal Medicine
关键词 糖尿病肾病 金水宝 依那普利 24h微量白蛋白尿 随机平行对照研究 Diabetic nephropathy Jinshui Bao Eenalapril Microalbuminuria 24h Random parallelcontrolled study
  • 相关文献

参考文献7

二级参考文献19

  • 1尤丹瑜,万建新,吴可贵.高血压肾损害[J].中华高血压杂志,2007,15(4):275-277. 被引量:69
  • 2American Diabetes Association. Diabetic nephropathy. Diabetes Care, 2000,25(Suppl 1):S85-S89.
  • 3Mogensen CE. Microalbuminuria as a risk marker in diabetic and non-diabetic patients . Diabetes Res Clin Pract, 2002,56(Suppl 1):S9.
  • 4Tan Y, Yang YN, Zhang ZG, et al. Urinary type Ⅳ collagen: a specific indicator of incipient diabetic nephropathy. Chin Med J, 2002,115:389-394.
  • 5DeFronzo RA. Diabetes renal disease. In: Porte D Jr. and Sherwin RS (eds). Ellenberg & Rifkin′s Diabetes Mellitus (5th ed). Beijing, China: McGraw-Hill, 1998.971-1008.
  • 6Diercks GF, Stroes ES, Boven AJ, et al. Urinary albumin excretion is related to cardiovascular risk indicators, not to flow-mediated vasodilation, in apparently healthy subjects. Atherosclerosis, 2002,163:121-126.
  • 7Diercks GF, van Boven AJ, Hillege JL, et al. The importance of microalbuminuria as a cardiovascular risk indicator: A review. Can J Cardiol, 2000,18:525-535.
  • 8前言[J].中国糖尿病杂志,2001,9.
  • 9Rosenberger C,Heyman SN,Rosen S, et al.Up- regulation of HIF in experimental acute renal fail- ure: evidence for a protective transcriptional re- sponse to hypoxia[J]. Kidney Int, 2005, 67(2): 531 - 542.
  • 10王咏梅,刘占全,樊文萍,张瑞芳,侴广程,李英.糖尿病大鼠肾组织Nephrin mRNA与Podocin mRNA表达的研究[J].河北职工医学院学报,2008,25(6):1-2. 被引量:3

共引文献317

同被引文献32

引证文献2

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部